Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?

Inclusion criteria

• Patients aged18-years old or over
• ECOG score between 0-2
• Inoperable stage III or stage IV melanoma
• Naïve of treatment or in progression after one or several treatment lines
• Give their written consent for the present study and be included in MelBase cohort.
• health insurance coverage.

Supplementary inclusion criteria for part II :

• skin or subcutaneous melanoma lesions
• agree and inform consent for a cutaneous biopsy or a tumor sample if presenting lymph nodes involvement if part of the usual clinical practice.

Exclusion criteria

• Pregnant and breastfeeding women
• Patients with psychiatric disorders
• Patients already included in another clinical trial
• Having received chemotherapy or radiotherapy during the last 4 weeks,
• Patient presenting another solid or blood cancer, chronic viral infection (e.g. HIV, HBV or HCV)
• Been treated with more than 10mg of steroids until the 4 weeks before inclusion.
• Refusal to participate to the study
• Patients under guardianship or curatorship
• Patients on state medical aid